Journal of Lipid Research, Vol 33, 1-7, Copyright © 1992 by Lipid Research, Inc.

ARTICLES

Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat

SE Kasim, RC LeBoeuf, S Khilnani, L Tallapaka, D Dayananda and KL Jen
Department of Medicine, Wayne State University, Detroit, MI.

Inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase have been approved for treatment of hypercholesterolemia in humans. This class of therapeutic agents, in addition to lowering plasma cholesterol, reduces plasma triglyceride levels. We have investigated the mechanism of triglyceride-lowering effect of lovastatin in the hypertriglyceridemic state by using a rodent model of hypertriglyceridemia and obesity, the Zucker obese (fa/fa) rat. Lovastatin treatment (4 mg/kg), as compared to placebo, caused a 338% reduction in plasma triglyceride (146 +/- 5 vs. 494 +/- 76 mg/dl), a 58% decrease in total cholesterol (99 +/- 13 vs. 156 +/- 18 mg/dl), and a 67% reduction in high density lipoprotein (HDL)-cholesterol (69 +/- 8 vs. 115 +/- 15 mg/dl). The fall seen in plasma triglyceride was due to a decrease in hepatic secretion of very low density lipoproteins (VLDL), determined after blocking the clearance of triglyceride-rich lipoproteins with Triton WR-1339. Lovastatin treatment did not affect either the activities of hepatic lipogenic enzymes, glucose-6-phosphate dehydrogenase, or malic enzyme, or the activities of the lipolytic enzymes of adipose tissue, lipoprotein lipase, or liver, hepatic triglyceride lipase. Supplementation of mevalonolactone in the diet partially reversed the changes in plasma triglyceride (265 +/- 37 vs. 146 +/- 5 mg/dl), but not in total or HDL-cholesterol. These data demonstrate that, in the hypertriglyceridemic Zucker rat model, HMG-CoA reductase inhibitors reduce the rate of secretion of VLDL and this effect can be partially reversed by administration of mevalonolactone.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				H. N. Ginsberg REVIEW: Efficacy and Mechanisms of Action of Statins in the Treatment of Diabetic Dyslipidemia J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 383 - 392. [Abstract] [Full Text] [PDF]

				D. M. Black, R. G. Bakker-Arkema, and J. W. Nawrocki An Overview of the Clinical Safety Profile of Atorvastatin (Lipitor), a New HMG-CoA Reductase Inhibitor Arch Intern Med, March 23, 1998; 158(6): 577 - 584. [Abstract] [Full Text] [PDF]

				K. Hayashi, M. Gohda, S. Matzno, Y. Kubo, H. Kido, T. Yamauchi, and N. Nakamura Possible Mechanism of Action of AE0047, a Calcium Antagonist, on Triglyceride Metabolism J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 882 - 890. [Abstract] [Full Text]

				E. J. Tisdale and W. E. Balch Rab2 Is Essential for the Maturation of Pre-Golgi Intermediates J. Biol. Chem., November 15, 1996; 271(46): 29372 - 29379. [Abstract] [Full Text] [PDF]

				S. Mui, M. Briggs, H. Chung, R. B. Wallace, T. Gomez-Isla, G. W. Rebeck, and B. T. Hyman A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the epsilon 4 allele Neurology, July 1, 1996; 47(1): 196 - 201. [Abstract] [Full Text] [PDF]